TIDMSAR
RNS Number : 1000H
Sareum Holdings PLC
13 November 2018
(AIM: SAR) 13 November 2018
Sareum Holdings plc
("Sareum" or "the Company")
Directorate Change
Michael Owen, PhD and Clive Birch appointed as Non-Executive
Directors
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development company, is pleased to announce the appointments
of Michael Owen, PhD and Clive Birch as Non-Executive
Directors.
Michael Owen (67) has worked in biomedical research, and in the
pharmaceutical and biotechnology industries for nearly 40 years. He
is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical
company based in Cambridge, UK, prior to which he worked for GSK
where he was SVP and Head of Research for Biopharmaceuticals
R&D. Dr Owen currently serves on the boards of several public
and private biotechnology companies in the UK, Europe and the USA,
including Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics
and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In
addition, Dr Owen is Chairman of ReNeuron's and Avacta's scientific
advisory boards, an advisor to Abingworth LLP and was until
recently an advisor to the CRT Pioneer Fund. Dr Owen received a MA
from Oxford University and a PhD from Cambridge University, and is
an elected member of the European Molecular Biology Organisation
and a Fellow of the Academy of Medical Sciences.
Clive Birch (65) is an Independent Non-Executive Director of
Cambridge Innovation Capital plc, a Cambridge-based builder of
technology and healthcare companies. He is a retired partner of
PricewaterhouseCoopers where his role was that of an auditor and
reporting accountant with an industry specialism in early stage
technology and healthcare companies. He was also part of the teams
involved in fund raising and listing those clients on various
markets. Mr Birch was also partner in charge of PwC's Cambridge
office for 15 years up to 2010, during which time he was
responsible for all aspects of that stand-alone business. Mr Birch
is a Governor of Birkbeck College, part of London University.
Dr Stephen Parker, Chairman of Sareum Holdings plc, said: "We
are delighted to welcome Mike and Clive to the board of Sareum.
They bring significant experience in the development of innovative
product candidates and technologies, and in financial management
and corporate governance, respectively. We believe this experience
and expertise will be highly valuable in guiding Sareum's future
growth and strategy to generate value for shareholders. In
consequence of these appointments, we will be constituting advisory
committees of the board which will increase our compliance with QCA
guidelines."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies.
Michael Owen, aged 67, has been a director of the following
companies during the five years preceding the date of this
announcement:
Current directorships: Avacta Group plc, ReNeuron plc,
GammaDelta Therapeutics Ltd, Ossianix Inc., Ossianix UK Ltd, Iskuda
Therapeutics Ltd, Zealand Pharma A/S, The Club Cricket Organisation
Ltd
Past directorship: BliNK Biomedical SAS
Clive Birch, aged 65, has been a director of the following
companies during the five years preceding the date of this
announcement:
Current directorships: Cambridge Innovation Capital plc, Pigeon
Land Limited, Pigeon Land 2 Limited, Pigeon (Shelford) Limited,
Pigeon (Uplands & Heigham) Limited and Chrib Ltd.
Clive Birch has been a partner of the following partnerships
during the five years preceding the date of this announcement:
Current partnerships: Pigeon East of England LP and Pigeon
(Sawston) LLP.
Save as set out above there are no further disclosures pursuant
to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
Neither Dr Owen nor Mr Birch has any beneficial interest in the
ordinary shares of the Company.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7282 9571
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7282 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory
responses in autoimmune diseases (e.g. psoriasis, rheumatoid
arthritis, inflammatory bowel diseases and lupus) and tumour cell
proliferation in certain cancers (e.g. T-cell acute lymphoblastic
leukaemia and some solid tumours). The Company is targeting first
human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFMMMMKZMGRZM
(END) Dow Jones Newswires
November 13, 2018 02:01 ET (07:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024